Fig. 3
From: Latozinemab, a novel progranulin-elevating therapy for frontotemporal dementia
Latozinemab decreases sortilin levels in WBCs and increases PGRN levels in plasma and CSF of cynomolgus monkeys. A–B Plasma A and CSF B concentrations of latozinemab antibody as a function of time. C Sortilin concentrations measured as a function of time in WBCs. D–E Plasma D and CSF E PGRN levels measured as a function of time. Male monkeys, 24–50 months of age, were used (n = 3 per group). All data represent the mean ± SEM. Dashed lines in C-E indicate baseline. CSF, cerebrospinal fluid; PGRN, progranulin